{"entity":{"id":"nct03803553","kind":"trial","name":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","aka":[],"tldr":"A phase 3 trial of encorafenib, binimetinib, trastuzumab and pertuzumab in colorectal cancer, run by Massachusetts General Hospital, active but no longer recruiting.","summary":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer is a phase 3, randomised interventional study registered as NCT03803553 by Massachusetts General Hospital, with a registry enrolment figure of 400 participants, started 2020-04-16 and due to reach its primary completion in 2026-12. Interventions recorded: FOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol; Trastuzumab + Pertuzumab. Conditions listed: Metastatic Colon Cancer; Stage III Colon Cancer. Primary outcome: Disease-free survival (DFS); Clearance rate of ctDNA. Colorectal eligibility wording from the registry: \"* Participants must have histologically confirmed resected Stage III adenocarcinoma of the colon\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03803553","url":"https://clinicaltrials.gov/study/NCT03803553"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["encorafenib","binimetinib","trastuzumab","pertuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03803553","phase":"3","setting":"Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer","sponsor":"Massachusetts General Hospital","enrolled":400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03803553/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}